Bifogade filer
Nanoform - Disclosure of Major Holdings according to Chapter 9, Section 10 of the Finnish Securities Markets Act
Prenumeration
Beskrivning
| Land | Finland |
|---|---|
| Lista | First North Finland |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Nanoform Finland Plc | Company Release | October 16, 2025 at 16:00:00 EEST
Helsinki, Finland – Nanoform Finland Plc (“Nanoform”) has, on October 15th, 2025, received a notification from Handelsbanken Fonder in accordance with chapter 9, section 10 of the Securities Market Act. According to the notification, holdings of Handelsbanken Fonder in Nanoform has decreased below the level of 5 per cent, as a result of share transactions concluded on September 30th, 2025.
Nanoform has one series of shares in which each share carries one vote. The percentages and numbers indicate the shareholding on the date of the notification received by Nanoform.
| Total positions of Handelsbanken Fonder subject to the notification obligation: | ||||
| % of shares and voting rights (total of 7.A) | % of shares and voting rights through financial instruments (total of 7.B) | Total of both in % (7.A + 7.B) | Total number of shares and voting rights of issuer | |
| Resulting situation on the date on which threshold was crossed or reached (Sep 30th, 2025) | 4,98% | 0% | 4,98% | 85 669 853 |
| Position of previous notification (Dec 7th, 2020) | 5.04% | 0% | 5.04% | 66 600 443 |
Notified details of the resulting situation on the date on which the threshold was crossed or reached:
A: Shares and voting rights:
| Class/type of shares ISIN code | Number of shares and voting rights | % of shares and voting rights | ||
| Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) | Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) | |
| FI4000330972 | 4 265 807 | 0 | 4,98% | 0 |
| SUBTOTAL A | 4 265 807 | 4,98% | ||
B: Financial Instruments according to SMA 9:6a:
| Type of financial instrument | Expiration date | Exercise/ Conversion Pe-riod | Physical or cash settlement | Number of shares and voting rights | % of shares and voting rights |
| - | - | - | - | - | - |
| Total B | - | - |
Notifications of major shareholdings and monthly ownership data can be found on the Company’s website www.nanoform.com.
For further information, please contact:
Peter Hänninen
General Counsel
peter.hanninen@nanoform.com
+358 50 353 0408
Henri von Haartman
Director of Investor Relations
hvh@nanoform.com
+46 7686 650 11
About Nanoform
Nanoform is the medicine performance-enhancing company that leverages best-in-class innovative nanoparticle engineering technologies, expert formulation, and scalable GMP API manufacturing to enable superior medicines for patients. The company focuses on reducing clinical attrition and on enhancing drug molecules’ performance through its nanoforming technologies and formulation services, from pre-clinical to commercial scale. Nanoform will help improve bioavailability and drug delivery profiles, drive differentiation, patient adherence and extend the lifecycle potential of products. Nanoform’s shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: DNB Carnegie Investment Bank AB, +46 8 588 685 70, certifiedadviser@dnbcarnegie.se. For more information, please visit www.nanoform.com.